Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

MARSEILLE, France, May 7, 2024–(BUSINESS WIRE)–Regulatory news:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company“), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2pm CEST/8am EDT, to provide an update on business progress during the first quarter of 2024.

Participants during the conference call will be:

• Hervé Brailly, CEO

• Sonia Quaratino, Executive Vice President, Chief Medical Officer

• Yannis Morel, Executive Vice President and Chief Operating Officer

• Frédéric Lombard, Senior Vice President, Chief Financial Officer

• Arvind Sood, Executive Vice President and President of US Operations

Virtual Event Details

The live broadcast will be available at the following link:
https://events.q4inc.com/attendee/244650312

Participants can also join by phone using the following registration link: https://registrations.events/direct/Q4I9730892

This information can also be found in the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company’s website for 90 days after the event.

About Innate Pharma

Innate Pharma SA is a global clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET^® (Aantibody-based NK cell ANDNager Therapeutics) proprietary platform.

Innate’s portfolio includes the leading proprietary program lacutamab, developed in advanced form cutaneous T-cell lymphomas and peripheral T-cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET^® multispecific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner with biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on X and LinkedIn.

Information about Innate Pharma shares

Disclaimer Regarding Forward-Looking Information and Risk Factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, are intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to the safety, progression and results of its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its drug candidates. products, the Company’s commercialization efforts and the Company’s continued ability to raise capital to finance its development. For further discussion of risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, see the Risk Factors (“Facteurs de Risque”) section of the Registration Document Universal filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website or the Innate Pharma website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the The Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

The story continues

This press release and the information contained therein do not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for Innate Pharma shares in any country.

View the original version on businesswire.com: https://www.businesswire.com/news/home/20240506536913/en/

Contacts

Investors
Innate Pharmaceuticals
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr

Media relations
New cap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu